Capricor says deramiocel meets primary endpoint in HOPE-3 Phase 3 Duchenne muscular dystrophy trial

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc.

CAPR

0.00
  • Capricor flagged new five-year open-label extension results for deramiocel in Duchenne muscular dystrophy, set for presentation June 27 at PPMD 2026.
  • The update showed sustained slowing of functional decline with stable heart function over the follow-up, supporting a durable benefit profile.
  • Previously reported HOPE-3 Phase 3 results will also be presented June 26, with the trial meeting its main functional endpoint and a key cardiac endpoint.
  • Safety remained consistent across studies, with no new safety signals reported.
  • The readouts come with deramiocel’s BLA under FDA review ahead of an Aug. 22, 2026, PDUFA target action date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606260905PRIMZONEFULLFEED9753077) on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.